Results 121 to 130 of about 21,696 (215)

Vitiligo: Ruxolitinib and Other Oral Treatment Options Beyond Ruxolitinib.

BACKGROUND: Vitiligo is a chronic autoimmune disorder marked by the loss of melanocytes, causing depigmented patches across the skin. Affecting up to 2% of the global population, vitiligo presents significant psychological impacts, particularly in those ...
Tan, Isabella J, Rao, Babar, Ghani, Hira, Tchack, Madeline, Ghofrani, Sasha   +4 more
core   +1 more source

Cord blood T regulatory cells synergize with ruxolitinib to improve GVHD outcomes

Frontiers in Transplantation
BackgroundAdoptive therapy with umbilical cord blood (UCB) T-regulatory (Treg) cells can prevent graft vs. host disease (GVHD). We hypothesize that UCB Tregs can treat GVHD and synergize with ruxolitinib, Jak2 inhibitor, to improve outcomes.MethodsUCB ...
Ke Zeng, Hongbing Ma, Meixian Huang, Mi-Ae Lyu, Tara Sadeghi, Christopher R. Flowers, Simrit Parmar   +6 more
doaj   +1 more source

Stabilitas dan Pengembangan Metode Estimasi Ruxolitinib Dengan RP-HPLC

Ruxolitinib adalah obat penghambat Janus Kinase 1 dan 2 oleh Food and Drud Administration (FDA) pada tahun 2011 yang ditetapkan sebagai pengobatan mielofibrosis dengan risiko sedang hingga tinggi. Ruxolitinib memiliki ketidakstabilan terhadap cahaya yang
Iswandi, Iswandi, Utami, Dila Wahyu, Supriyadi, Supriyadi   +2 more
core   +1 more source

Evaluating the Efficacy of Cytokine‐Directed Therapies in the Management of VEXAS Syndrome

ACR Open Rheumatology, Volume 8, Issue 10, October 2026.
Objective To evaluate the efficacy of cytokine‐directed therapies in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory somatic) syndrome using previously proposed treatment response criteria. Methods All patients with genetically confirmed VEXAS syndrome who received targeted therapies with JAK inhibitors (JAKi), tumor necrosis factor α inhibitors
Daniel Montes, Hannah E. Langenfeld, Andrew C. Hanson, Cynthia S. Crowson, Mrinal M. Patnaik, Ronald S. Go, Kambiz Kalantari, Yael Kusne, Terra Lasho, Abhishek A. Mangaonkar, Horatiu Olteanu, Kaaren K. Reichard, Megan M. Sullivan, David S. Viswanatha, Kenneth J. Warrington, Matthew J. Koster   +15 more
wiley   +1 more source

Ruxolitinib for Emergency Treatment of COVID‐19–Associated Cytokine Storm: Findings From an Expanded Access Study

The Clinical Respiratory Journal
Introduction This expanded access program (EAP) provided ruxolitinib (oral, selective Janus kinase [JAK]1/JAK2 inhibitor) for emergency treatment of COVID‐19–associated cytokine storm in patients eligible for hospitalization (NCT04355793).
Jeffrey Weinstein, Nikhil Jagan, Shawnta Lorthridge‐Jackson, J. E. Hamer‐Maansson, Peg Squier   +4 more
doaj   +1 more source

CO‐Rebreathing in Essential Thrombocythemia and Polycythemia Vera. A Revival of an Old Methodology to Improve Diagnosis and Phlebotomy Decisions

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT The diagnostic landscape for the Philadelphia‐negative myeloproliferative neoplasms (MPNs), particularly in distinguishing Essential Thrombocythemia (ET) from Polycythemia Vera (PV), is compromised. The gold standard for diagnosing PV—measurement of red cell mass (RCM) by radioisotope dilution—has been largely abandoned, leading to widespread ...
Hans C. Hasselbalch, Morten Kranker Larsen, Lea Løffler, Camilla Andersen, Isabella Davidsen, Mette Grymer Jensen, Jonas Bechlund, Lasse Kjær, Vibe Skov, Henning Bay Nielsen, Carsten Lundby   +10 more
wiley   +1 more source

A myelofibrosis case that develops mycobacterial infection after ruxolitinib treatment

, 2017
Ruxolitinib is a novel therapeutic agent which is being used in the treatment of myelofibrosis. In the literature, there are reports of opportunistic infections along with tuberculosis during ruxolitinib treatment.
Malkan, ÜMİT YAVUZ, HAZNEDAROĞLU, İBRAHİM CELALETTİN   +1 more
core  

Ruxolitinib for the Treatment of Essential Thrombocythemia

, 2018
. Deregulated Janus Kinase 2 (JAK2) activation is central to the pathogenesis of most myeloproliferative neoplasms (MPNs), of which essential thrombocythemia (ET) is the most common entity.
Patrick Harrington, Donal McLornan, Arief Gunawan, Natalia Garcia-Curto, Deepti Radia, Claire Harrison   +5 more
core   +1 more source

Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE

Frontiers in Immunology
BackgroundUmbilical cord blood (UCB)-derived CD4+CD25+CD127low regulatory T cells (Tregs) can decrease albuminuria and anti-dsDNA IgG in systemic lupus erythematosus (SLE).
Mi-Ae Lyu, Ximing Tang, Maria Gabriela Raso, Meixian Huang, Ke Zeng, Tara Sadeghi, Christopher R. Flowers, Simrit Parmar   +7 more
doaj   +1 more source

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis

eJHaem
Bone marrow fibrosis (BMF) is a pathological feature of myelofibrosis, with higher grades associated with poor prognosis. Limited data exist on the association between outcomes and BMF changes.
Stephen T. Oh, Srdan Verstovsek, Vikas Gupta, Uwe Platzbecker, Timothy Devos, Jean‐Jacques Kiladjian, Donal P. McLornan, Andrew Perkins, Maria Laura Fox, Mary Frances McMullin, Adam J. Mead, Miklos Egyed, Jiri Mayer, Tomasz Sacha, Jun Kawashima, Mei Huang, Bryan Strouse, Ruben Mesa   +17 more
doaj   +1 more source